Market Movers (8-K)
OQB
CTT Pharmaceutical Holdings, Inc. announced the U.S. Patent Office has granted a continuation-in-part patent for its micelle delivery technology, now covering nicotine, vitamins, and caffeine across various oral dosage forms.
Quarterly Earnings (10-Q)
OQB
CTT Pharmaceutical Holdings, Inc. filed its quarterly report for the period ended June 30, 2026, highlighting ongoing net losses and a going concern warning from auditors, alongside progress in patent applications and potential European partnerships.
Capital raise
Worse than expected
Insider Trading (Form 4)
See all →OQB
Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on September 22, 2026.
OQB
Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on September 24, 2026.
OQB
Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on September 18, 2026.
OQB
Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on September 14, 2026.
OQB
Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on September 8, 2026.
OQB
Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on September 3, 2026.
New Public Companies (S-1)
OQB
CTT Pharmaceutical Holdings, Inc. has filed an S-1/A amendment to register up to 6,250,000 shares of common stock for resale by RH2 Equity Partners, issued under an Equity Line of Credit.
Capital raise
Delay expected
OQB
CTT Pharmaceutical Holdings, Inc. has filed an amended S-1 registration statement to allow for the resale of up to 6,250,000 shares of common stock by RH2 Equity Partners, issued under an Equity Line of Credit.
Capital raise
OQB
CTT Pharmaceutical Holdings, Inc. has filed an amended S-1 registration statement to allow for the resale of up to 6,250,000 shares of common stock by RH2 Equity Partners, issued under a committed equity line of credit.
Capital raise
OQB
CTT Pharmaceutical Holdings, Inc. has filed an amended S-1 registration statement detailing the potential resale of up to 6,250,000 shares of common stock by RH2 Equity Partners.
Capital raise
OQB
CTT Pharmaceutical Holdings, Inc. filed an amended S-1 registration statement to facilitate a $10 million equity line of credit with RH2 Equity Partners.
Capital raise